Document:

<Page>

                                                                    Exhibit 10.7

                        MANUFACTURE AND SUPPLY AGREEMENT

     This Manufacture and Supply Agreement (this "Agreement"), dated as of _____
__, 2004 (the "Effective Date"), is by and between Hospira, Inc., a Delaware
corporation ("Hospira"), and Abbott Laboratories, an Illinois corporation
("Abbott").

                                    RECITALS

           WHEREAS, the board of directors of Abbott has determined that it is
in the best interests of Abbott and its shareholders to separate Abbott's core
hospital products business from its other existing businesses;

           WHEREAS, in order to effectuate the foregoing, Abbott and Hospira
have entered into a Separation and Distribution Agreement of even date herewith
(the "Separation and Distribution Agreement"), which provides, among other
things, subject to the terms and conditions set forth therein, for the
separation and the distribution to Hospira of certain assets and the assumption
by Hospira of certain liabilities, and for the execution and delivery of certain
other agreements in order to facilitate and provide for the foregoing; and

           WHEREAS, in connection with the transactions contemplated by the
Separation and Distribution Agreement, Hospira desires Abbott to manufacture and
supply the products set forth on EXHIBIT A attached hereto (individually, the
"Product" and collectively, the "Products") to Hospira, and Abbott is willing to
manufacture and supply such Products to Hospira in accordance with this
Agreement.

           NOW, THEREFORE, in consideration of the mutual covenants and
undertakings contained herein, and subject to and on the terms and conditions
herein set forth, the parties hereto agree as follows:

                             ARTICLE 1- DEFINITIONS

     1.1   For the purpose of this Agreement the following terms will have the
following meanings:

     "Abbott" has the meaning set forth in the Preamble.

     "Act" means the United States Food, Drug and Cosmetic Act, as amended,
including all regulations promulgated thereunder.

     "Agreement" means this API Supply Agreement, including any amendments
hereto and each of the Exhibits hereto.

     "cGMPs" shall mean the current Guidelines for Good Manufacturing Practice
set forth in 21 C.F.R. (Parts 210 and 211), as may be amended from time to time,
and the current International Conference on Harmonization Good Manufacturing
Practice Guidelines as promulgated by the FDA, as may be amended from time to
time, as applicable.

<Page>

     "Discretionary Changes" has the meaning set forth in SECTION 3.6(c).

     "Effective Date" has the meaning set forth in the Preamble.

     "Exhibit D Products" means the Products listed on EXHIBIT D.

     "Exhibit E Products" means the Products listed on EXHIBIT E.

     "Exhibit D Successive Term" has the meaning set forth in SECTION 4.1.

     "Exhibit E Successive Term" has the meaning set forth in SECTION 4.1.

     "FDA" means the United States Food and Drug Administration and any
successor agency thereto.

     "Hospira" has the meaning set forth in the Preamble.

     "Information" means information, whether or not patentable or
copyrightable, in written, oral, electronic or other tangible or intangible
forms, including studies, reports, records, books, contracts, instruments,
surveys, discoveries, ideas, concepts, know-how, techniques, designs,
specifications, drawings, blueprints, diagrams, models, prototypes, samples,
flow charts, data, computer data, disks, diskettes, tapes, computer programs or
other software, marketing plans, customer names, communications by or to
attorneys (including attorney-client privileged communications), memos and other
materials prepared by attorneys or under their direction (including attorney
work product), and other technical, financial, employee or business information
or data.

     "Initial Term" has the meaning set forth in SECTION 4.1.

     "Parties" means the parties to this Agreement.

     "Person" means an individual, a general or limited partnership, a
corporation, a trust, a joint venture, an unincorporated organization, a limited
liability entity, any other entity and any Regulatory Authority.

     "Prime Rate" means the rate which Citibank N.A. (or its successor or
another major money center commercial bank agreed to by the Parties) announces
as its prime lending rate, as in effect from time to time

     "Product" and "Products" have the meanings set forth in the Recitals.

     "Product Specifications" shall mean those product, labeling and performance
specifications for the Products filed with the FDA or other appropriate
Regulatory Authorities, including Product formula and materials required for the
manufacture of the Products that are to be purchased and supplied under this
Agreement, which specifications may be amended from time to time by the written
agreement of the Parties.

                                        2
<Page>

     "Quality Agreement" means: (i) with respect to Products manufactured in the
United States, the Quality Agreement by and between Abbott and Hospira,
substantially in the form of EXHIBIT B, as the same may be amended; and (ii)
with respect to Products manufactured outside of the United States, the
International Technical Agreement by and between Abbott and Hospira, consistent
with the Product Specifications and substantially in the form of EXHIBIT C, as
the same may be amended.

     "Regulatory Authority" means any federal, state or local or international
regulatory agency, department, bureau or other governmental entity including the
FDA which is responsible for issuing approvals, licenses, registrations or
authorizations necessary for the manufacture, use, storage, import, transport or
sale of any Product in a regulatory jurisdiction.

     "Required Changes" has the meaning set forth in SECTION 3.6(b).

     "Separation and Distribution Agreement" has the meaning set forth in the
Recitals.

     "Subsidiary" of any Person means another Person that is directly or
indirectly controlled by such first Person. As used herein, "control" means the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through
ownership of voting securities or other interests, by contract or otherwise. For
the avoidance of doubt, TAP Pharmaceutical Products Inc., TAP Finance Inc. and
TAP Pharmaceuticals Inc. are not Subsidiaries of Abbott as that term is used in
this Agreement.

     "Third Party" means any Person other than Abbott, any Abbott Subsidiary,
Hospira and any Hospira Subsidiary.

     "Transfer Plan" has the meaning set forth in SECTION 6.1.

               ARTICLE 2- ORDERS, PRICING, PAYMENT AND CONFORMANCE

     2.1   FORECASTS AND ORDERS.

           (a)   PURCHASE AND SALE OF PRODUCT. Pursuant to the terms and
                 conditions of this Agreement and for the duration of this
                 Agreement, Abbott shall manufacture, sell and deliver the
                 Products to Hospira in the quantities requested pursuant to
                 SECTION 2.1(b) and Hospira shall purchase and take delivery of
                 its worldwide requirements of the Products exclusively from
                 Abbott.

           (b)   ROLLING FORECAST. Simultaneously with the execution of this
                 Agreement, Hospira shall provide Abbott with an eighteen (18)
                 month non-binding forecast of Hospira's best estimate of its
                 future requirements of the Products, which forecast shall be
                 updated by the fifteenth (15th) day of each month during the
                 term of this Agreement. Such forecast shall (i) specify the
                 Product, the item number, and quantity of each Product and (ii)

                                        3
<Page>

                 be consolidated by month. For the Exhibit D Products, the first
                 six (6) months of each rolling eighteen (18) month forecast
                 shall constitute a firm order for such Product quantities. For
                 the Exhibit E Products, the first four (4) months of each
                 rolling eighteen (18) month forecast shall constitute a firm
                 order for such Product quantities. For purposes of
                 clarification of the forecast, the firm order period described
                 above shall not include the current month (I.E. the firm order
                 period for Exhibit D Products commencing June 2004 would
                 include orders placed through December 2004). As updated by the
                 fifteenth (15th) day of the month, such updated forecast shall
                 restate the balance of the firm order period remaining prior to
                 such updated forecast and include in the firm order period the
                 requirements for the next month of such updated forecast.

           (c)   LONG-RANGE FORECAST. For capacity planning purposes, Hospira
                 shall also provide Abbott with a three (3) year non-binding
                 forecast prior to January 1st of each year during the term of
                 this Agreement.

           (d)   FIRM ORDERS. All firm purchase orders, or alternative forms of
                 communication, delivered in accordance with the provisions of
                 SECTION 2.1(b) shall be for an amount no less than eighty
                 percent (80%) nor more than one hundred twenty percent (120%)
                 of the most recent forecast for such period; provided, however,
                 in the event such firm order exceeds one hundred twenty percent
                 (120%) of the most recent forecast for such Products, Abbott
                 shall use its commercially reasonable efforts to manufacture
                 and deliver to Hospira, in addition to the forecasted
                 quantities, such excess of the Products ordered by Hospira
                 exceeding one hundred twenty percent (120%) of the most recent
                 forecast for such Products. If any such forecast or update
                 exceeds Abbott's anticipated capacity, Abbott shall so notify
                 Hospira within fourteen (14) days of receipt of the forecast or
                 update.

           (e)   FIRM ORDER CHANGES. If Hospira requests changes to firm orders
                 within the firm order period specified in SECTION 2.1(b),
                 Abbott shall attempt to accommodate the changes within
                 reasonable manufacturing capabilities and efficiencies. Abbott
                 shall advise Hospira of the costs associated with making any
                 such change, and the Parties shall mutually agree upon the
                 amount of such costs prior to Abbott proceeding to make the
                 change. Upon such mutual agreement, Abbott shall make such
                 change and Hospira shall be responsible for paying such costs.

           (f)   PURCHASE ORDER TERMS. Hospira shall issue a purchase order, or
                 an agreed upon method of communicating its requirements of the
                 Products, to Abbott. Each purchase order or any acknowledgment
                 thereof, if any, whether printed, stamped, typed, or written,
                 shall be governed by the terms

                                        4
<Page>

                 of this Agreement and none of the provisions of such purchase
                 order or acknowledgment shall be applicable except those
                 specifying Product and quantity ordered, delivery dates,
                 special shipping instructions and invoice information. All
                 Product orders hereunder shall be in order quantities as
                 agreed between the Parties. Abbott shall deliver the Products
                 in such firm order quantities and on such delivery dates as
                 are specified in the applicable purchase order and, if no such
                 purchase order is issued, as specified in the firm order
                 period of Hospira's eighteen (18) month forecasts and monthly
                 updates provided pursuant to SECTION 2.1(b). Abbott shall
                 receive Hospira's prior approval prior to making any
                 adjustments to Product order quantities and/or shipping dates.

     2.2   PRICE; ADJUSTMENT PAYMENT; SHIPMENT.

           (a)   INITIAL TERM PRICES. The prices for each Product for the
                 Initial Term of the Agreement shall be those set forth in
                 EXHIBIT A attached hereto. The prices set forth in EXHIBIT A
                 shall be subject to adjustment as provided in SECTION 2.2(b).

           (b)   PRICE ADJUSTMENTS. The prices set forth in EXHIBIT A shall be
                 subject to adjustment as follows:

                    (i)  In the event Hospira elects to extend the term of this
                         Agreement beyond the Initial Term, as set forth in
                         SECTION 4.1, (A) the prices for the Products for the
                         first twelve (12) month period subsequent to the
                         Initial Term shall be adjusted from the prices set
                         forth in EXHIBIT A, as such prices may have been
                         adjusted pursuant to SECTION 2.2(b)(ii) or SECTION
                         2.2(c), to reflect the increase in the Producer Price
                         Index for the prior twenty-four (24) month period, and
                         (B) the prices for the Products for the twelve (12)
                         month period subsequent to the period described in (A)
                         above shall be adjusted from the prices set forth in
                         EXHIBIT A, as such prices may have been adjusted
                         pursuant to SECTION 2.2(b)(ii) or SECTION 2.2(c) and
                         (A) above, to reflect the increase in the Producer
                         Price Index for the prior twelve (12) month period.

                    (ii) In the event that due to material unforeseen and
                         unavoidable reasons, the aggregate standard cost of
                         manufacturing the Products hereunder (e.g. raw
                         materials or other circumstances outside the control of
                         Abbott, but not including labor and overhead costs)
                         increases by five percent (5%) or more, Abbott shall
                         promptly provide notice to Hospira of such increase
                         (which notice shall document the reasons for such
                         increase)

                                        5
<Page>

                         and the Parties shall meet within thirty (30) days of
                         Abbott's notice to negotiate an appropriate price
                         adjustment. If the Parties are unable to negotiate an
                         appropriate price adjustment, the Parties shall resolve
                         the conflict in accordance with the procedures set
                         forth in SECTION 8.6.

           (c)   MATERIALS COST REDUCTIONS. In the event that Hospira assists
                 Abbott in reducing its costs of purchasing materials from
                 suppliers in connection with Abbott's manufacture of Products
                 hereunder, such cost reductions realized by Hospira shall be
                 shared equally by Abbott and Hospira, net of all implementation
                 costs.

           (d)   PAYMENT TERMS. Abbott shall invoice Hospira upon delivery of
                 Product or transfer of Product into Hospira's inventory
                 pursuant to the U.S. Transition Services Agreement between the
                 Parties dated as of the date hereof, as applicable. Hospira
                 shall make payment net thirty (30) days from the date of
                 Abbott's invoice; provided, however, that Hospira shall notify
                 Abbott of any disputed invoice as soon as practicable and a
                 timeline for resolving such dispute shall be mutually agreed by
                 the Parties within forty-five (45) days of the date of the
                 disputed invoice. Failure to pay a disputed invoice shall not
                 be deemed a breach of this Agreement by Hospira and will not
                 relieve Abbott from its commitment to continue to supply
                 Products hereunder. Product invoices that remain unpaid within
                 thirty (30) days after the invoice date, other than invoices
                 being disputed in accordance with the terms set forth above,
                 shall bear interest at a rate per annum equal to Prime Rate
                 plus two percent (2%); provided however, any invoices disputed
                 by Hospira and resolved in favor of Abbott shall be subject to
                 such late payment fee as of the invoice date until paid in
                 full. All payments hereunder shall be made in U.S. dollars.

           (e)   TAXES. Any federal, state, county or municipal sales or use
                 tax, excise, customs charges, duties or similar charge, or any
                 other tax assessment (other than that assessed against income),
                 license, fee or other charge lawfully assessed or charged on
                 the manufacture, sale or transportation of Product sold
                 pursuant to this Agreement shall be paid by Hospira.

           (f)   DELIVERY. Abbott shall deliver the Products to Hospira or into
                 Hospira's inventory pursuant to the U.S. Transition Services
                 Agreement between the Parties dated as of the date hereof, as
                 applicable, F.C.A. Abbott's manufacturing facility and title
                 shall pass to Hospira at such point. Shipment to Hospira's
                 designated location, if applicable, shall be at Hospira's
                 expense and via a carrier designated by Hospira. Hospira shall
                 be the importer of record for all Products imported hereunder,
                 if any, and

                                        6
<Page>

                 shall assume all associated costs and import activities,
                 whether customs or transportation-related.

           (g)   NO SET-OFF. Hospira's obligation to make any required payments
                 under this Agreement shall not be subject to any right of
                 offset, set-off, deduction or counterclaim, however arising.

     2.3   EXPIRATION/RETEST DATING. So long as Hospira purchases Exhibit D
Products in full batch quantities, such Products, when shipped to Hospira
hereunder, shall have at least two-thirds of their original shelf life and at
least two-thirds of their first retest date remaining at the date of shipment,
unless otherwise agreed in writing by Hospira.

     2.4   REJECTION. Hospira shall perform such samplings and tests as may be
required under the Quality Agreement to determine whether the Product meets the
Product Specifications, is not adulterated or misbranded within the meaning of
the Act and complies with all applicable statutes, laws, rules and regulations,
including without limitation, cGMPs. Any Product not refused pursuant to the
terms of the Quality Agreement shall be deemed accepted. If Hospira wishes to
refuse acceptance, Hospira shall inform Abbott of its refusal to accept the
Product, and the reasons therefor. In the event that Hospira refuses acceptance,
Abbott, upon confirmation of the reasons for refusal of the Product, shall
replace the defective Product. If Abbott and Hospira do not agree on the refusal
or rejection of Product, then either Party may refer the matter for final
analysis to a specialized laboratory of national reputation acceptable to both
Parties for the purpose of determining the results. Any determination by such
laboratory shall be binding upon both Parties. If such independent laboratory
determines that the shipment conformed to the requirements of this Agreement,
Hospira shall bear all expenses of shipping, including freight charges, and
testing such shipment samples. If Abbott or such independent laboratory confirms
that such shipment did not meet the requirements of this Agreement, Abbott shall
replace, at no cost to Hospira, the portion of the shipment which does not
conform and bear all expenses of shipping, including freight charges, and
testing the shipment samples.

     2.5   TESTING; CERTIFICATE OF ANALYSIS AND CONFORMANCE. Abbott shall,
pursuant to the terms of the Quality Agreement, perform the necessary testing
and provide the required documentation to release the Products to Hospira, which
such documentation may include a certificate of analysis for each shipment of
the Products.

              ARTICLE 3- WARRANTIES, COVENANTS AND INDEMNIFICATION

     3.1   GENERAL WARRANTIES AND INDEMNIFICATION.

           (a)   ABBOTT REPRESENTATIONS AND WARRANTIES. Abbott represents and
                 warrants to Hospira that none of the Products Abbott delivers
                 to Hospira pursuant to this Agreement shall, at the time of
                 delivery, be adulterated or misbranded within the meaning of
                 the Act or within the meaning of any applicable

                                        7
<Page>

                 state or municipal law in which the definitions of adulteration
                 and misbranding are substantially the same as those contained
                 in the Act, as the Act and such laws are constituted and
                 effective at the time of delivery, and will not be an article
                 which may not under the provisions of Sections 404 and 505 of
                 the Act be introduced into interstate commerce. Abbott further
                 represents and warrants to Hospira that each of the Products
                 Abbott delivers to Hospira pursuant to this Agreement shall be
                 free from defects in material and workmanship and shall be
                 manufactured: (a) in accordance and conformity with the Product
                 Specifications provided by Hospira; and (b) in compliance with
                 all applicable statutes, laws, rules or regulations, including
                 those relating to the environment, food or drugs and
                 occupational health and safety, including, without limitation,
                 those enforced or promulgated by the FDA (including, without
                 limitation, compliance with cGMPs). Abbott further represents
                 and warrants to Hospira that Abbott's performance of its
                 obligations under this Agreement will not result in a material
                 violation or breach of any agreement, contract, commitment or
                 obligation to which Abbott is a party or by which it is bound
                 and will not conflict with or constitute a default under its
                 Certificate of Incorporation or corporate bylaws. ABBOTT MAKES
                 NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO
                 PRODUCT. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
                 WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY
                 AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY
                 ABBOTT.

           (b)   HOSPIRA REPRESENTATIONS AND WARRANTIES. Hospira represents and
                 warrants that it shall provide Product Specifications to Abbott
                 with respect to the Products. Hospira further represents and
                 warrants to Abbott that Hospira's performance of its
                 obligations under this Agreement will not result in a material
                 violation or breach of any agreement, contract, commitment or
                 obligation to which Hospira is a party or by which it is bound
                 and will not conflict with or constitute a default under its
                 corporate charter or bylaws.

           (c)   RECALLS. Hospira shall, as between the Parties, be responsible
                 for the handling of all recalls of the Exhibit D Products,
                 including without limitation, withdrawal of the Products from
                 the market and regulatory actions. Abbott shall, as between the
                 Parties, be responsible for the handling of all recalls of the
                 Exhibit E Products, including without limitation, withdrawal of
                 the Products from the market and regulatory actions. Costs for
                 recalls of any Product to the extent arising out of, relating
                 to, or resulting from a breach by Abbott of this Agreement
                 shall be borne by Abbott, including reimbursement to Hospira
                 for costs incurred for the handling of such recall. In
                 addition, Abbott shall indemnify Hospira against any and all
                 costs and expenses which Hospira may incur as a result of any
                 such recall to the extent Abbott is responsible. Costs for

                                        8
<Page>

                 any recalls of any Product to the extent Abbott is not liable
                 under this Agreement or any other agreement between the Parties
                 relating to the Products shall be borne by Hospira. In
                 addition, Hospira shall indemnify Abbott against any and all
                 costs and expenses which Abbott may incur as a result of any
                 recall to the extent Hospira is responsible. The Parties shall
                 promptly advise and consult with one another with respect to
                 any recall related to the manufacture of any Product, and each
                 Party shall participate, if requested by the controlling Party,
                 in all meetings with the FDA and/or equivalent foreign
                 regulatory body regarding such recall. The expense of each
                 Party's participation in any such meetings shall be borne by
                 the Party responsible for the recall.

           (d)   INDEMNIFICATION BY ABBOTT. Abbott shall indemnify, defend and
                 hold harmless Hospira, its affiliates, officers, directors and
                 employees from and against all claims, causes of action, suits,
                 costs and expenses (including reasonable attorney's fees),
                 losses or liabilities pursuant to this Agreement and asserted
                 by Third Parties to the extent such arise out of, result from
                 or relate to: (i) Abbott's breach of any representation or
                 warranty set forth in SECTION 3.1(a); (ii) any violation or
                 infringement of any proprietary right of any Third Party to the
                 extent relating to, arising out of or resulting from Abbott's
                 manufacturing processes used in the manufacture of Products
                 pursuant to this Agreement (exclusive of the Product
                 Specifications or any Hospira proprietary rights); and (iii)
                 any negligent, wrongful act, or willful misconduct or omission
                 on the part of Abbott, its officers, directors, employees,
                 agents or representatives relating to Abbott's performance
                 hereunder.

           (e)   INDEMNIFICATION BY HOSPIRA. Hospira shall indemnify, defend and
                 hold harmless Abbott, its affiliates, officers, directors and
                 employees from and against all claims, causes of action, suits,
                 costs and expenses (including reasonable attorney's fees),
                 losses or liabilities pursuant to this Agreement and asserted
                 by Third Parties to the extent such arise out of, result from
                 or relate to: (i) Hospira's breach of any representation or
                 warranty set forth in SECTION 3.1(b); (ii) any violation or
                 infringement of any proprietary right of any Third Party to the
                 extent relating to, arising out of or resulting from the
                 Exhibit D Products, other than Abbott's manufacturing processes
                 used in the manufacture of Products pursuant to this Agreement;
                 (iii) the use of or lack of safety or efficacy of the Exhibit D
                 Products; and (iv) any negligent, wrongful act, or willful
                 misconduct or omission on the part of Hospira, its officers,
                 directors, employees, agents or representatives relating to
                 Hospira's performance hereunder.

           (f)   CONDITIONS OF INDEMNIFICATION. If either Party seeks
                 indemnification from the other hereunder, it shall promptly
                 give notice to the other Party of any

                                        9
<Page>

                 such claim or suit threatened, made or filed against it which
                 forms the basis for such claim of indemnification and shall
                 cooperate fully with the other Party in the investigation and
                 defense of all such claims or suits. The indemnifying Party
                 shall have the option to assume the other Party's defense in
                 any such claim or suit with counsel reasonably satisfactory to
                 the other Party. No settlement or compromise shall be binding
                 on a Party hereto without its prior written consent, such
                 consent not to be unreasonably delayed or withheld.

           (g)   LIMITATIONS ON LIABILITY. FOR EACH TWELVE (12) MONTH PERIOD
                 DURING WHICH THIS AGREEMENT IS IN EFFECT, COMMENCING AS OF THE
                 EFFECTIVE DATE, THE MAXIMUM LIABILITY OF ABBOTT AND ITS
                 SUBSIDIARIES TO, AND THE SOLE REMEDY OF, HOSPIRA AND ANY OF ITS
                 SUBSIDIARIES WITH RESPECT TO ANY AND ALL CLAIMS ARISING UNDER
                 OR IN CONNECTION WITH THIS AGREEMENT, REGARDLESS OF THE THEORY
                 UPON WHICH THE LIABILITY IS PREMISED, SHALL NOT EXCEED ABBOTT'S
                 PROFITS HEREUNDER, WHICH SHALL BE DEEMED TO BE EQUAL TO THE
                 AMOUNT OF THE MARK-UP RECEIVED BY ABBOTT DURING SUCH TWELVE
                 (12) MONTH PERIOD AS SET FORTH ON EXHIBIT A AND AS MAY BE
                 ADJUSTED PURSUANT TO THE TERMS OF SECTION 2.2(b).

           (h)   NO CONSEQUENTIAL DAMAGES. NEITHER PARTY SHALL BE LIABLE TO THE
                 OTHER FOR INDIRECT, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR
                 PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS
                 AND PUNITIVE DAMAGES RESULTING FROM ANY BREACH OF THIS
                 AGREEMENT, EVEN IF THE PARTY HAS BEEN ADVISED OF THE
                 POSSIBILITY OF SUCH DAMAGES, AND EACH PARTY HEREBY WAIVES ON
                 BEHALF OF ITSELF AND ITS SUBSIDIARIES ANY CLAIM FOR SUCH
                 DAMAGES, INCLUDING ANY CLAIM FOR PROPERTY DAMAGE OR LOST
                 PROFITS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE.

           (i)   The foregoing limitations on liability in this SECTION 3.1
                 shall not apply to: (i) Abbott's liability for breaches of
                 confidentiality under ARTICLE VII, or (ii) Abbott's obligations
                 for claims brought by Third Parties arising out of Abbott's
                 gross negligence or willful misconduct.

     3.2   MANUFACTURE OF THE PRODUCTS.

           (a)   MANUFACTURING STANDARDS. Abbott shall manufacture and deliver
                 the Products to Hospira at all times in full compliance with
                 the Act, cGMPs,

                                       10
<Page>

                 Product Specifications for each Product, any other applicable
                 regulatory requirements and the requirements set forth in the
                 Quality Agreement. Abbott shall maintain during the term of
                 this Agreement and for a period thereafter consistent with
                 Abbott's policies and standard cGMP requirements, all records
                 as are necessary or appropriate to demonstrate compliance with
                 the Act, cGMPs, Product Specifications, any other applicable
                 regulatory requirements and the Quality Agreement. If Abbott
                 fails to comply with cGMPs in a material manner, as
                 demonstrated by an observation of a Regulatory Authority,
                 Abbott shall use reasonable commercial efforts to remedy such
                 material deviation.

           (b)   MANUFACTURING PROCESS. Abbott shall provide all raw materials,
                 components, packaging, containers, labeling, release testing,
                 quality control, equipment, labor, and other services and
                 materials necessary for the manufacture of the Products, as
                 part of the price set forth in EXHIBIT A, except as otherwise
                 provided by Hospira. Abbott shall be responsible for vendor
                 quality approval for vendors of such materials all of which
                 shall comply with Product Specifications.

           (c)   NON-STANDARD EQUIPMENT COSTS. If non-standard, specialized
                 equipment is required to manufacture any Exhibit D Product for
                 Hospira, Hospira shall pay the cost of such equipment, subject
                 to Hospira's prior approval of such costs, which approval shall
                 not be unreasonably withheld. Abbott shall advise Hospira of
                 specialized equipment required and the estimated costs
                 associated with the purchase and installation of such
                 equipment. After Hospira approves such costs, Abbott shall
                 install the equipment and bill Hospira for the associated
                 costs. Hospira shall make payment to Abbott no later than
                 thirty (30) days from the date of Abbott's invoice. Title to
                 the equipment shall be in Abbott's name. If Abbott wishes to
                 use the specialized equipment for manufacture of a product
                 other than an Exhibit D Product for Hospira, Abbott and Hospira
                 shall meet and discuss the technical and practical
                 ramifications of such use and appropriate compensation to
                 Hospira. Abbott will be responsible for insuring, maintaining
                 and repairing all Hospira-purchased equipment located at
                 Abbott's facility to the same level of care of Abbott-owned
                 equipment. In the event of loss of any Hospira-purchased
                 equipment while in Abbott's possession during the term of this
                 Agreement, Hospira shall receive the replacement funds for such
                 equipment received by Abbott arising from its insurance claim
                 for such equipment. Upon the termination or expiration of this
                 Agreement, Abbott shall, as agreed by the Parties, transfer
                 ownership of any equipment purchased by Abbott pursuant to this
                 SECTION 3.2(d) to Hospira or maintain ownership of the
                 equipment by paying Hospira the greater of the then current
                 book or fair market value of the equipment. Hospira shall bear
                 all costs associated with the removal of equipment from
                 Abbott's facility if the Parties elect to transfer ownership

                                       11
<Page>

                 of such equipment. This provision shall not apply to any
                 standard equipment normally used or required for the
                 manufacture of Exhibit D Product or for additional standard
                 equipment required to increase production capacity or
                 efficiency at Abbott's manufacturing facility. =

           (d)   AUDIT. Hospira shall have the right, either by itself or
                 through independent outside auditors or consultants, not more
                 than once per year during the term of this Agreement, unless
                 reasonable cause is shown, to inspect and audit any areas of
                 Abbott's facilities in which any portion of the manufacturing
                 of the Products is performed for the examination of production
                 or quality records or to perform cGMP audits, at its sole
                 expense, on reasonable advance notice, during Abbott's normal
                 business hours in a manner that does not interfere unreasonably
                 with Abbott's operations. Any such auditor or consultant shall
                 enter into an agreement with the Parties on terms in which such
                 independent auditor shall agree to maintain the confidentiality
                 of the information obtained during the course of such audit.

     3.3   REGULATORY MATTERS.

           (a)   PERMITS, REGISTRATIONS, LICENSES AND APPROVALS. Abbott shall be
                 responsible for maintaining all regulatory and governmental
                 permits, registrations, licenses and approvals necessary to
                 manufacture and deliver the Exhibit D Products to Hospira. To
                 the extent Abbott requires the assistance of Hospira in order
                 to fulfill its obligations pursuant to this SECTION 3.3(a),
                 Hospira agrees to fully cooperate and assist Abbott at
                 Hospira's expense. Upon the expiration or termination of this
                 Agreement, Abbott shall use reasonable commercial efforts to
                 cooperate with Hospira to transfer and maintain such permits,
                 licenses, registrations and approvals.

           (b)   REPORTING REQUIREMENTS. During the term of this Agreement,
                 Abbott will be responsible for any reporting of matters
                 regarding the manufacture of Products to any applicable
                 Regulatory Authority in accordance with pertinent laws and
                 regulations. Abbott shall promptly furnish copies of any such
                 reports to Hospira. Abbott shall also advise Hospira of any
                 occurrences or information that arises out of Abbott's
                 manufacturing activities that have or could reasonably be
                 expected to have adverse regulatory compliance and/or reporting
                 consequences concerning the Products.

           (c)   INSPECTIONS. Abbott shall be responsible, at Abbott's sole
                 expense, for handling and responding to any FDA or other
                 governmental agency inspections with respect to the manufacture
                 of the Exhibit D Products during the term of this Agreement.
                 Abbott shall provide to Hospira any

                                       12
<Page>

                 Information reasonably requested by Hospira and all Information
                 requested by the FDA or any other governmental agency
                 concerning any governmental inspection related to the Exhibit D
                 Products. To the extent Abbott requires the assistance of
                 Hospira in order to fulfill its obligations pursuant to this
                 SECTION 3.3(c), Hospira agrees to fully cooperate and assist
                 Abbott at Hospira's expense.

                 In the event Abbott or any of the Products are inspected by any
           applicable Regulatory Authority, Abbott shall notify Hospira as soon
           as practicable of (i) any such inspection with reasonable advance
           notice, (ii) any written alleged violations or deficiencies relating
           to the manufacturing facility at which Products are manufactured,
           packaged or stored, and (iii) the corrective action to be taken, and
           shall promptly contest such alleged violations or deficiencies in
           good faith or take the required corrective action, each at Abbott's
           sole expense.

     3.4   COMPLAINTS AND RECALLS.

           (a)   Hospira shall notify Abbott promptly of any Product complaints
                 involving Abbott's manufacture in sufficient time to allow
                 Abbott to evaluate the complaints and assist Hospira in
                 responding to such complaints.

           (b)   In the event that Abbott should be required to initiate a
                 recall, field alert, Product withdrawal or field correction
                 with respect to any Product provided under this Agreement,
                 Abbott shall immediately notify Hospira in writing. In the
                 event that Hospira believes that a recall, field alert, Product
                 withdrawal, or field correction is necessary with respect to
                 any Product provided under this Agreement, Hospira shall
                 promptly so notify Abbott.

     3.5   INSURANCE. During the term of this Agreement, Abbott and Hospira
shall maintain their own respective product liability insurance with respect to
the Products, in such amounts and with such scope of coverage as are adequate to
cover their respective obligations under this Agreement and as are appropriate
for companies of like size in like industries, taking into account the scope of
activities contemplated herein.

     3.6   MANUFACTURING CHANGES.

           (a)   PRODUCT CHANGES. Abbott shall not make any changes to the
                 Product Specifications and/or manufacturing that would require
                 approval from, or notification to, any Regulatory Authority
                 without the prior written consent of Hospira, which such
                 consent shall not be unreasonably withheld. The timing of
                 Abbott's notice to Hospira of any such change shall permit

                                       13
<Page>

                 adequate time for Hospira to make any necessary regulatory
                 filings and obtain any necessary approval thereof from a
                 Regulatory Authority prior to the change being implemented.

           (b)   REQUIRED CHANGES. For changes to the Product Specifications or
                 manufacturing relating solely to the Products that are required
                 by laws and other regulatory requirements (including, without
                 limitation, cGMP), or by medical or scientific concerns as to
                 the toxicity, safety and/or efficacy of the Products
                 (collectively, "Required Changes"), the Parties shall cooperate
                 in making such changes promptly.

           (c)   DISCRETIONARY CHANGES. Abbott shall consider in good faith any
                 request by Hospira to make changes to the Product
                 Specifications or manufacturing that are not Required Changes,
                 including, but not limited to, changes to the existing Product,
                 Product line extensions, or changes to the existing or
                 additional packaging (collectively, "Discretionary Changes").
                 Any analytical improvements shall be considered Discretionary
                 Changes unless requested or required by Regulatory Authorities
                 in which case such improvements shall be considered a Required
                 Change. Any change requested by Abbott which is not a Required
                 Change shall be made only with the written consent of Hospira,
                 which consent shall not be unreasonably withheld.

           (d)   COSTS OF CHANGES. Any and all costs associated with Required
                 Changes shall be borne by Hospira. Any Discretionary Changes
                 initiated by either party shall be agreed to by the Parties
                 including which Party or Parties shall be responsible for the
                 funding of such Discretionary Change. Notwithstanding the
                 foregoing, any Required Changes during the first three (3)
                 months after the Effective Date that are required in order to
                 comply with laws and other Regulatory Requirements in effect as
                 of the Effective Date shall be at Abbott's sole cost and
                 expense.

                         ARTICLE 4- TERM AND TERMINATION

     4.1   TERM. This Agreement shall have an initial term of two (2) years
commencing on the Effective Date (the "Initial Term"). With respect to the
Exhibit D Products, Hospira may extend this Agreement beyond the Initial Term by
giving written notice of such extension to Abbott not less than twelve (12)
months prior to expiration of the Initial Term. Such extension of the Initial
Term (the "Exhibit D Successive Term") shall continue for a period equal to the
amount of time required by Hospira to (i) identify and qualify an alternative
supplier for the Exhibit D Products, or (ii) negotiate a new agreement with
Abbott for the supply of such Products; provided, however, that such Exhibit D
Successive Term shall not exceed two (2) years. For the duration of the Exhibit
D Successive Term, Hospira shall (i) use reasonable commercial efforts to
identify and qualify such alternative supplier for the Exhibit D Products, or
(ii) engage in good faith negotiations with Abbott regarding such new agreement.
With respect

                                       14
<Page>

to the Exhibit E Products, Abbott may extend this Agreement beyond the Initial
Term by giving written notice of such extension to Hospira not less than twelve
(12) months prior to expiration of the Initial Term. Any such extension of the
Initial Term (the "Exhibit E Successive Term") shall continue for a period equal
to the amount of time required by Abbott to (i) identify and qualify an
alternative source for the finishing of the Exhibit E Products, or (ii)
negotiate a new agreement with Hospira for the finishing of such Products;
provided, however, that such Exhibit E Successive Term shall not exceed two (2)
years. For the duration of the Exhibit E Successive Term, Abbott shall (i) use
commercially reasonable efforts to identify and qualify such alternative source
for finishing the Exhibit E Products, or (ii) engage in good faith negotiations
with Hospira regarding such new agreement. Abbott may terminate the Exhibit E
Successive Term by giving Hospira not less than twelve (12) months written
notice of such termination. During the Initial Term and any Successive Term, the
Parties may mutually agree to early termination of this Agreement, on a
Product-by-Product basis, at any time.

     4.2   MATERIAL BREACH. Either Party may terminate this Agreement upon sixty
(60) days' prior written notice to the other Party if the other Party is in
material breach of any term of this Agreement, as determined according to the
dispute resolution procedures set forth in SECTION 8.6 or as agreed in writing
by the breaching party, and such breaching party fails to cure that breach
within such sixty (60) day period. Any final order of debarment which has a
material adverse effect on sales of the Products shall constitute a material
breach of the Agreement for purposes of this SECTION 4.2.

     4.3   INSOLVENCY. This Agreement may be terminated upon thirty (30) days'
prior written notice by either Party at any time during this Agreement if (a)
the other Party shall file in any court pursuant to any statute of any
government in any country a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or
trustee of the Party or of its assets; (b) any Third Party proposes a written
agreement of composition for extension of its debts; (c) the other Party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within sixty (60) days
after filing thereof; (d) the other Party shall be a party to any dissolution or
liquidation, or (e) the other Party shall make a general assignment for the
benefit of its creditors.

     4.4   DIVESTITURE OR CLOSURE OF PLANT. If Abbott divests to a Third Party
or closes any of its manufacturing facilities used in manufacturing of any of
the Exhibit D Products , Abbott shall continue to manufacture such Products in
an FDA approved alternative facility approved by Hospira prior to the transfer
of the manufacturing of such Products, such approval not to be unreasonably
withheld or delayed, or if applicable, obligate the purchaser of such
facility(ies) to assume Abbott's obligations hereunder as a condition to closing
such divestiture. Abbott is solely responsible for all costs associated with any
transfer of manufacturing pursuant to this SECTION 4.4.

     4.5   INVENTORY TRANSFER. Upon the termination of this Agreement, Abbott
shall transfer all remaining firm orders of Products pursuant to SECTION 2.1(b),
work in process and raw materials relating to the Products manufactured pursuant
to this Agreement to Hospira at

                                       15
<Page>

Hospira's expense, unless such termination shall have been as a result of a
breach of this Agreement by Abbott or the early termination of this Agreement
pursuant to SECTION 4.1, in which case such inventory, work in process and raw
materials shall be returned at Abbott's expense.

     4.6   EFFECT OF TERMINATION. Termination of this Agreement shall not affect
any obligations of either Party incurred prior to its termination, including,
without limitation, each Party's obligations with respect to any firm orders
that have been submitted or deemed to be submitted pursuant to ARTICLE 2 hereof.

                         ARTICLE 5-INTELLECTUAL PROPERTY

     5.1   ABBOTT'S PROPRIETARY RIGHTS. Abbott has granted no license, express
or implied, to Hospira to use Abbott proprietary technology, know-how or rights
relating to its manufacturing processes for the Products other than for the
purposes of this Agreement. If Abbott, in its sole discretion, deems patentable
any improvement or invention related to Abbott's proprietary technology,
know-how or rights relating to its manufacturing processes made or reduced to
practice in the course of this Agreement and if such improvement or invention
relates exclusively to Abbott's manufacturing operations in general, then Abbott
shall solely own and shall be entitled to apply for patent protection on such
improvements or inventions at Abbott's expense and risk. Subject to the
preceding sentence, Hospira shall be entitled to all such rights relating to any
improvement or invention relating to Abbott proprietary technology, know-how or
rights relating exclusively to the Product or the manufacture thereof. Abbott
hereby grants (and shall have deemed to have granted) to Hospira without any
further action by Abbott, a fully-paid, non-exclusive, perpetual, irrevocable,
royalty-free license to use such improvements or inventions of the Product
Specification solely for the purposes of the manufacture of the Products.

     5.2   HOSPIRA'S PROPRIETARY RIGHTS. Hospira has granted no license, express
or implied, to Abbott to use Hospira's proprietary technology, know-how or
rights relating to the Products, other than for the purposes of this Agreement.
If Hospira, in its sole discretion, deems patentable any improvement or
invention related to the Products or to Hospira's proprietary technology,
know-how or rights relating to the Products, then Hospira shall solely own and
shall be entitled to apply for patent protection on such improvements or
inventions at its expense and risk.

                          ARTICLE 6- TECHNICAL TRANSFER

     6.1   TRANSFER PLAN. The Parties hereby agree that effective at the time of
any expiration or termination of this Agreement or at Hospira's request in the
event that Hospira desires to qualify a source other than Abbott to manufacture
a Product, the Parties shall meet and mutually agree upon a reasonable plan to
transfer the Product Specifications from Abbott to Hospira or Hospira's
designees (the "Transfer Plan").

     6.2   PROPRIETARY RIGHTS ASSOCIATED WITH TRANSFER PLAN. Hospira shall
receive, pursuant to this SECTION 6.2, the necessary Product Specifications and
know-how and certain intellectual

                                       16
<Page>

property developed in the course of this Agreement as described in SECTION 5.1
to permit Hospira or Hospira's designee to manufacture the Products in
accordance with the Product Specifications in place at the time of the transfer.
At any time after the Effective Date, Abbott shall reasonably cooperate with
Hospira's efforts to qualify a source other than Abbott to manufacture the
Products and obtain necessary approvals for such qualifications. The effective
date of such transfer shall be specified by Hospira upon written notice to
Abbott (provided that such transfer shall not relieve Abbott of any obligations
accrued prior to such transfer date, including the responsibility for firm
orders already placed and any remaining inventory).

     6.3   COSTS OF TRANSFER PLAN. In the event that this Agreement terminates
for any reason except Abbott's material breach, all direct actual out-of-pocket
costs incurred by Abbott in connection with each such Transfer Plan, and
Abbott's time (at the current staff rates) incurred in connection with each such
Transfer Plan, shall be the sole responsibility of Hospira. In the event that
this Agreement terminates as a result of Abbott's material breach, all direct
actual out-of-pocket costs incurred [by Abbott] in connection with each such
Transfer Plan, and Abbott's time (at the current staff rates) incurred in
connection with each such Transfer Plan, shall be the sole responsibility of
Abbott.

                           ARTICLE 7 - CONFIDENTIALITY

     7.1   CONFIDENTIALITY. Subject to SECTION 7.3, Abbott, on behalf of
itself and each Abbott Subsidiary, and Hospira, on behalf of itself and each
Hospira Subsidiary, agrees to hold, and to cause its respective directors,
officers, employees, agents, accountants, counsel and other advisors and
representatives to hold, in strict confidence, with at least the same degree of
care that applies to Abbott's confidential and proprietary information pursuant
to policies in effect as of the Effective Date, all Information concerning the
other and the other's Subsidiaries that is either in its possession (including
Information in its possession prior to the Effective Date) or furnished by the
other or the other's Subsidiaries or their respective directors, officers,
employees, agents, accountants, counsel and other advisors and representatives
at any time pursuant to this Agreement, and will not use any such Information
other than for such purposes as may be expressly permitted hereunder, except, in
each case, to the extent that such Information has been (i) in the public domain
through no fault of such Party or its Subsidiaries or any of their respective
directors, officers, employees, agents, accountants, counsel and other advisors
and representatives, (ii) later lawfully acquired from other sources by such
Party (or any of its Subsidiaries) which sources are not themselves bound by a
confidentiality obligation, or (iii) independently generated without reference
to any proprietary or confidential Information of the other Party.

     7.2   NO RELEASE; RETURN OR DESTRUCTION. Each Party agrees not to release
or disclose, or permit to be released or disclosed, any such Information to any
other Person, except its directors, officers, employees, agents, accountants,
counsel and other advisors and representatives who need to know such
Information, and except in compliance with SECTION 7.3. Without limiting the
foregoing, when any Information furnished by the other Party after the Effective
Date pursuant to this Agreement is no longer needed for the purposes
contemplated by this Agreement, each Party will promptly after receiving a
written request from the other Party either return to the other Party all such
Information in a tangible form (including all copies

                                       17
<Page>

thereof and all notes, extracts or summaries based thereon) or certify to the
other Party that it has destroyed such Information (and such copies thereof and
such notes, extracts or summaries based thereon).

     7.3   PROTECTIVE ARRANGEMENTS. In the event that either Party or any of its
Subsidiaries either determines on the advice of its counsel that it is required
to disclose any Information pursuant to applicable law or the rules or
regulations of any Regulatory Authority or receives any demand under lawful
process or from any Regulatory Authority to disclose or provide Information of
any other Party that is subject to the confidentiality provisions hereof, such
Party shall notify the other Party prior to disclosing or providing such
Information and shall cooperate at the expense of the requesting Party in
seeking any reasonable protective arrangements requested by such other Party.
Subject to the foregoing, the Person that received such request may thereafter
disclose or provide Information to the extent required by such law (as so
advised by counsel) or by lawful process or such Regulatory Authority.

                            ARTICLE 8 - MISCELLANEOUS

     8.1   CORPORATE ORGANIZATION AND AUTHORITY. Each Party represents and
warrants that it is a company duly organized, validly existing, and in good
standing under the laws of the jurisdiction wherein it is organized, and that it
has all necessary power and authorization to assume its obligations under this
Agreement, and to discharge them pursuant to the terms hereof.

     8.2   PUBLIC ANNOUNCEMENTS. Neither Party shall make any publicity
releases, interviews, or other dissemination of Information concerning this
Agreement or its terms, or either Party's performance hereunder, to
communication media, financial analysts or others without the written approval
of the other Party, which approval shall not unreasonably be withheld. Either
Party may upon notice to the other make any disclosure in filings with
regulatory agencies as required by law or applicable court order; provided that
the other Party shall have the opportunity to consult on such disclosures and
filings.

     8.3   FORCE MAJEURE. Neither Party shall be liable to the other if, and to
the extent that, the performance or delay in performance of any of its
obligations under this Agreement is prevented, restricted, delayed or interfered
with due to circumstances beyond the reasonable control of such Party,
including, but not limited to, government legislation, fires, floods,
explosions, epidemics, accidents, acts of God, wars, riots, strikes, lockouts or
other concerted acts of workers and/or acts of government. The Party claiming an
event of force majeure shall promptly notify the other Party in writing, and
provide full particulars of the cause or event and the date of first occurrence
thereof, as soon as possible after the event and also keep the other Party
informed of any further developments. The Party so affected shall use its
commercially reasonable efforts to remove the cause of non-performance, and both
the Parties shall resume performance hereunder with the utmost dispatch when
such cause is removed unless this Agreement has previously been terminated under
ARTICLE 4 hereof.

                                       18
<Page>

     8.4   ENTIRE AGREEMENT. This Agreement and the Exhibits hereto contain the
entire agreement and understanding between the Parties with respect to the
subject matter hereof and supersede all prior agreements and understandings,
whether written or oral, relating to such subject matter; provided, that except
as otherwise expressly agreed by the Parties, nothing herein shall modify or
supersede the Separation and Distribution Agreement or any of the other
agreements contemplated therein.

     8.5   AMENDMENT AND WAIVER. This Agreement may be amended only by a writing
which specifically states that such an amendment is its purpose and which is
signed by both Parties. No course of dealing between the Parties or failure by
either Party to exercise any right or remedy hereunder shall constitute an
amendment to this Agreement or a waiver of any other right or remedy or the
later exercise of any right or remedy.

     8.6   GOVERNING LAW; DISPUTE RESOLUTION. This Agreement will be governed by
and construed and interpreted in accordance with the laws of the State of
Illinois irrespective of the choice of laws principles of the State of Illinois,
as to all matters, including matters of validity, construction, effect,
enforceability, performance and remedies. Any controversy or claim arising out
of or relating to this Agreement, or the breach thereof, shall be resolved
exclusively by the alternative dispute resolution process described in EXHIBIT
F.

     8.7   ASSIGNMENT. Neither this Agreement nor any of the rights and
obligations of a Party hereunder shall be assignable or transferable by such
Party without the prior written consent of the other Party; provided, however,
that this Agreement shall be assignable by either Party with the prior written
consent of the other Party (which consent shall not be unreasonably withheld,
delayed or conditioned) in connection with a sale, by sale of stock, sale of
assets, merger or otherwise, of all or substantially all of one or more
businesses, business units or product lines of the assigning Party.

     8.8   NATURE OF AGREEMENT. In operating under this Agreement, each Party
shall act independently and this Agreement shall not be construed as creating
any partnership, joint venture or incorporated business entity. Neither Party
shall have any authority to incur any liability or obligation whatsoever on
behalf of the other.

     8.9   NOTICE. All notices or other communications under this Agreement must
be in writing and will be deemed to be duly given (a) when delivered in person,
(b) upon transmission via confirmed facsimile transmission, provided that such
transmission is followed by delivery of a physical copy thereof in person, via
U.S. first class mail, or via a private express mail courier, or (c) two days
after deposit with a private express mail courier, in any such case addressed as
follows:

     If to Abbott, to:

           Abbott Laboratories
           100 Abbott Park Road

                                       19
<Page>

           Building AP6D, Dept. 364
           Abbott Park, Illinois 60064-6020
           Attn:  General Counsel
           Facsimile: (847) 938-1561

     If to Hospira to:

           Hospira, Inc.
           Legal Department
           Dept. _____
           275 North Field Drive
           P.O. Box 5045
           Lake Forest, IL 60045-5045
           Attn: General Counsel
           Facsimile: (224) 212-_________________

Any Party may, by notice to the other Party, change the address to which such
notices are to be given.

                                       20
<Page>

           IN WITNESS WHEREOF, the Parties hereto have affixed hereunto their
authorized signature as of the date first above written:

                                           HOSPIRA, INC.

                                           By:
                                              ---------------------------------
                                           Name:
                                                -------------------------------
                                           Title:
                                                 -----------------------------

                                           ABBOTT LABORATORIES

                                           By:
                                              ---------------------------------
                                           Name:
                                                -------------------------------
                                           Title:
                                                  ------------------------------

                                       21<Page>

                                                                    Exhibit 10.8

                                     FORM OF
            TRANSITION MARKETING AND DISTRIBUTION SERVICES AGREEMENT

       THIS TRANSITION MARKETING AND DISTRIBUTION SERVICES AGREEMENT, dated as
of ____________, 2004, is by and between Hospira, Inc., a Delaware corporation
("HOSPIRA") and ______________________, a _____________ corporation with its
principal place of business at __________________________ ("DISTRIBUTOR") and is
effective as of the Effective Time (as defined below).

       WHEREAS, the board of directors of Abbott (as defined below) has
determined that it is appropriate and advisable to separate its core hospital
products business from Abbott's other businesses by contributing the core
hospital products business and related assets to Hospira and distributing the
shares of Hospira to the shareholders of Abbott, so that the core hospital
products business will be owned by Hospira;

       WHEREAS, the transfer to Hospira of the Delayed Ex-U.S. Commercial Assets
(as defined below) and the Delayed Ex-U.S. Commercial Liabilities (as defined
below) within the Territory (as defined below) cannot be accomplished until
Hospira obtains regulatory approvals for the transfer of the marketing
authorizations for the Products (as defined below) and establishes its own
operations in the Territory; and

       WHEREAS, Hospira and Distributor have agreed that, until the transfer of
the marketing authorizations for the Products to Hospira is accomplished and
Hospira establishes its own operations in the Territory, Distributor shall
promote, market, distribute and sell the Products within the Territory for
Hospira, but without assuming the commercial risks associated with such
activities, and Hospira shall assume the commercial risks associated with
Distributor's promotional, marketing, distributing and selling activities.

       NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the Parties hereto agree as follows:

                                        1
<Page>

1.     DEFINITIONS. Capitalized terms used herein have the meanings ascribed to
them in the Separation and Distribution Agreement (as defined below) unless
otherwise defined herein. Reference is made to SECTION 8.11 regarding the
interpretation of certain words and phrases used in this Agreement (as defined
below). In addition, for the purpose of this Agreement, the following terms
shall have the meanings set forth below.

       "2004 PLAN" means the 2004 plan attached as SCHEDULE 1 of this Agreement.

       "ABBOTT" means Abbott Laboratories, an Illinois corporation.

       "ABBOTT SUBSIDIARY" means any Subsidiary of Abbott other than Hospira and
any Hospira Subsidiary.

       "ADJUSTED PLAN FOR 2005" means the 2004 Plan adjusted for expected
inflation for 2005 in the country in which the Distributor maintains its
principal place of business with the amount of such adjustment to be determined
by Abbott no later than August 31, 2004 by requesting from each of three (3)
major money center commercial banks an estimate of inflation rates for 2005 for
such country and averaging the responses received from such banks; PROVIDED that
if not all banks respond for such country, then the average shall be taken using
the data provided by the responding banks.

       "ADJUSTED PLAN FOR 2006" means the Adjusted Plan for 2005 adjusted for
expected inflation for 2006 in the country in which the Distributor maintains
its principal place of business with the amount of such adjustment to be
determined by Abbott no later than August 31, 2005 by requesting from each of
three (3) major money center commercial banks an estimate of inflation rates for
2006 for such country and averaging the responses received from such banks;
PROVIDED that if not all banks respond for such country, then the average shall
be taken using the data provided by the responding banks.

       "AGREEMENT" means this Transition Marketing and Distribution Services
Agreement and each of the Schedules hereto.

       "BOOK VALUE" means, for any Delayed Ex-U.S. Commercial Liability, the
recorded amount of such Delayed Ex-U.S. Commercial Liability in the accounting
books of Distributor as of a particular date, calculated in accordance with
Distributor's practices as in effect at such time.

       "BUSINESS ENTITY" means any corporation, general or limited partnership,
trust, joint venture, unincorporated organization, limited liability entity or
other entity.

                                    2

<Page>

       "CLOSING DATE" has the meaning set forth in SECTION 7.1 of this
Agreement.

       "CLOSING REPORT" has the meaning set forth in SECTION 7.4 of this
Agreement.

       "COLLECTION PERIOD" means the collection periods set forth in SCHEDULE 2
of this Agreement.

       "DELAYED EX-U.S. COMMERCIAL ASSETS" means: (i) the Hospira Assets (other
than Delayed Ex-U.S. Manufacturing Assets) that are held by Distributor as of
the Effective Time; and (ii) the Hospira Assets that are held by Distributor of
the type described in subsection (v) of the definition of Hospira Assets in the
Separation and Distribution Agreement.

       "DELAYED EX-U.S. COMMERCIAL LIABILITIES" means: (i) the Hospira
Liabilities (other than Delayed Ex-U.S. Manufacturing Liabilities) of
Distributor that remain outstanding as of the Effective Time; and (ii) the
Hospira Liabilities of Distributor of the type described in subsection (vi) of
the definition of Hospira Liabilities in the Separation and Distribution
Agreement.

       "DISTRIBUTION DATE" means the date determined by the board of directors
of Abbott, in its sole discretion, for the consummation of the Distribution.

       "DISTRIBUTOR ACTIVITIES" has the meaning set forth in SECTION 4.1 of this
Agreement.

       "EFFECTIVE TIME" means 11:59 p.m. Eastern Time on the Distribution Date.

       "FACTORED ASSETS" has the meaning set forth in SECTION 7.2 of this
Agreement.

       "FACTORED LIABILITIES" has the meaning set forth in SECTION 7. 2 of this
Agreement.

       "FACTORING ADJUSTMENT" means the difference resulting from subtracting:
(a) the present discounted value, calculated utilizing the Local Interest Rate
for the period from the Closing Date through the remaining applicable Collection
Period, of the Net Book Value of the Factored Assets, the Book Value of the
Factored Liabilities and the Book Value of the intercompany trade payables
related to the Products outstanding as of the Closing Date; from (b) the Net
Book Value of the Factored Assets, the Book Value of the Factored Liabilities
and the Book Value of the intercompany trade payables related to the Products
outstanding as of the Closing Date.

       "FIXED FEE RETAINER" means the following monthly payments payable in
local currency: (i) for each month of the period commencing on the date after
the Distribution Date and ending on November 30, 2004, one hundred five percent
(105%) of the expenses included in the 2004

                                    3

<Page>

Plan for each such month; (ii) for each month of the period commencing on
December 1, 2004 and ending on November 30, 2005, one hundred five percent
(105%) of the expenses for each such month in the Adjusted Plan for 2005; and
(iii) for each month during the period commencing on December 1, 2005 and ending
on the last day of the Term, one hundred five percent (105%) of the expenses for
each such month in the Adjusted Plan for 2006.

       "GUIDELINES" has the meaning set forth in SECTION 4.4 of this Agreement.

       "HOSPIRA" has the meaning set forth in the Recitals.

       "HOSPIRA SUBSIDIARY" means any Subsidiary of Hospira. For greater
clarity, the Transferred Entities shall be deemed to have been Hospira
Subsidiaries at all times prior to the Effective Time.

       "LOCAL CLOSING" has the meaning set forth in SECTION 7.1 of this
Agreement.

       "LOCAL INTEREST RATE" means the prevailing local per annum interest rate
for ninety (90) day borrowings as in effect on the Distribution Date in the
country in which Distributor maintains its principal place of business,
determined on a basis consistent with Abbott's treasury practices as of the
Distribution Date.

       "NET ASSET VALUE" means the difference between the Net Book Value of the
Delayed Ex-U.S. Commercial Assets and the Book Value of the Delayed Ex-U.S.
Commercial Liabilities held by Distributor as of a particular date.

       "NET BOOK VALUE" means, for any Delayed Ex-U.S. Commercial Asset, the
recorded costs of such Delayed Ex-U.S. Commercial Asset in the accounting books
of the Distributor, adjusted for related valuation reserves, amortization and
depreciation, as of a particular date, calculated in accordance with
Distributor's practices as in effect at such time.

       "NOTICE OF LOCAL CLOSING" has the meaning set forth in SECTION 6.2 of
this Agreement.

       "PARTIES" means the parties to this Agreement.

       "PERSON" means any: (i) individual; (ii) Business Entity; or (iii)
Governmental Authority.

       "PRODUCTS" has the meaning set forth in SECTION 2.1 of this Agreement.

       "PURCHASE PRICE" has the meaning set forth in SECTION 7.3 of this
Agreement.

                                    4
<Page>

       "PURCHASER" means Hospira or a Hospira Subsidiary or designee that shall
purchase the Delayed Ex-U.S. Commercial Assets and assume the Delayed Ex-U.S.
Commercial Liabilities at the applicable Local Closing.

       "SEPARATION AND DISTRIBUTION AGREEMENT" means the Separation and
Distribution Agreement by and between Abbott and Hospira dated _____________.

       "SUBSIDIARY" of any Party means another Business Entity that is directly
or indirectly controlled by such Party. As used herein, "control" means the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through
ownership of voting securities or other interests, by contract or otherwise. For
the avoidance of doubt, TAP Pharmaceutical Products Inc., TAP Finance Inc. and
TAP Pharmaceuticals Inc. are not Subsidiaries of Abbott as that term is used in
this Agreement.

       "TERM" has the meaning set forth in SECTION 6.1 of this Agreement.

       "TERMS AND CONDITIONS" has the meaning set forth in SECTION 3.1 of this
Agreement.

       "TERRITORY" has the meaning set forth in SECTION 2.2 of this Agreement.

       "THIRD PARTY" means any Person other than Abbott, any Abbott Subsidiary,
Hospira and any Hospira Subsidiary.

       "TRANSITION SERVICES PERIOD" means the period from the Effective Time
until the earlier of: (i) the Closing Date; and (ii) except as otherwise
provided in SECTION 8.1 of this Agreement, the second anniversary of the
Distribution Date.

2.     DISTRIBUTION

       2.1    PRODUCTS. For purposes of this Agreement, "PRODUCTS" means the
       Hospira Products that are sold in the Territory by Distributor as of the
       Effective Time and such other products that are added by the Parties
       pursuant to the provisions of this Agreement.

       2.2    TERRITORY. Hospira hereby appoints Distributor, and Distributor
       hereby accepts such appointment, to promote, market, distribute and sell
       the Products within the country or countries listed on SCHEDULE 3 of this
       Agreement (the "TERRITORY") in its own name, acting as Hospira's
       non-exclusive distributor.

       2.3    DISTRIBUTION CHANNELS. Distributor has the right to promote,
       market, distribute and sell the Products to customers in the Territory
       through all channels of distribution either

                                    5
<Page>

       by itself or by way of any Third Parties, including wholesalers,
       sub-distributors and agents. The promotion, marketing, distribution or
       sale of Products by any Third Party shall require the prior written
       consent of Hospira unless: (i) such Third Party was engaged in the
       promotion, marketing, distribution or sale of the Products prior to the
       Effective Time; or (ii) Distributor is obtaining analogous services for
       Abbott products from such Third Party. Distributor shall not grant to any
       wholesalers, sub-distributors or agents any rights greater than those
       that are granted by Hospira to Distributor under this Agreement.

       2.4    INDEPENDENT CONTRACTOR. Each of the Parties hereby acknowledges
       that the Parties are separate entities, each of which has entered into
       this Agreement for independent business reasons. The relationship of the
       Parties hereunder is that of independent contractors and nothing
       contained herein shall be deemed to create a joint venture, partnership
       or any other relationship.

       2.5    PERFORMANCE BY SUBSIDIARIES. All rights and obligations of a Party
       under or pursuant to this Agreement may be exercised, satisfied, met or
       fulfilled, in whole or in part, by such Party directly or, in the case of
       Distributor, by any Abbott Subsidiary and, in the case of Hospira, by any
       Hospira Subsidiary.

3.     PURCHASE OF PRODUCTS AND TERMS OF SALE

       3.1    ORDERS; TERMS AND CONDITIONS. Distributor shall purchase from
       Hospira, and Hospira shall sell to Distributor, such quantities of
       Products as Distributor may order from time to time pursuant to the terms
       of this Agreement. The price, terms and conditions of each sale of
       Products to Distributor shall be subject to the then-applicable terms and
       conditions of sale agreed in writing from time to time by Distributor and
       Hospira (the "TERMS AND CONDITIONS"). The Terms and Conditions in effect
       as of the Effective Time are set forth in SCHEDULE 4 of this Agreement.
       Any provisions in any preprinted order form or order document used by
       Hospira or Distributor are explicitly rejected and shall be null and void
       and of no force or effect.

       3.2    PAYMENTS. (a)   During each month of the Term, Hospira shall pay
       to Distributor the Fixed Fee Retainer and such other amounts as described
       in SCHEDULE 4 of this Agreement.

                        (b)   Distributor shall pay Hospira the amounts
       described in SCHEDULE 4 of this Agreement under the terms and conditions
       described therein.

                                    6
<Page>

                        (c)   Hospira hereby authorizes Distributor to offset
       the amounts due by Hospira to Distributor under subsection (a) from the
       amounts payable by Distributor to Hospira under SCHEDULE 4 of this
       Agreement. If the difference resulting from such offset is a positive
       number, Distributor shall pay the difference to Hospira in accordance
       with SCHEDULE 4 of this Agreement. If, by contrast, such difference is a
       negative number, Hospira shall pay such difference to Distributor in
       accordance with SCHEDULE 4 of this Agreement.

       3.3    LATE PAYMENTS. All amounts due under this Agreement that are not
       paid when due shall bear interest at a rate per annum equal to the sum
       of: (i) Local Interest Rate; and (ii) two percent (2%).

4.     DISTRIBUTOR'S ACTIVITIES

       4.1    DISTRIBUTOR ACTIVITIES. (a)   During the Term, Distributor shall
       perform regulatory, pharmacovigilance, promotional, marketing,
       distribution and selling activities for the Products in the Territory in
       a manner that is: (i) substantially similar in nature, quality,
       timeliness, volume and level to those services contemplated by the
       Parties in preparing the 2004 Plan; (ii) consistent with the Guidelines,
       the Abbott Code of Business Conduct and applicable local laws; and (iii)
       subject to Hospira's commercially reasonable instructions with respect to
       such activities (the "DISTRIBUTOR ACTIVITIES"). Nothing in this Agreement
       shall require either of the Parties to perform or cause to be performed
       any service or activity in a manner that would constitute a violation of
       applicable laws, the marketing authorizations for the Products or the
       Abbott Code of Business Conduct.

                        (b)   Hospira hereby acknowledges that, unless
       Distributor otherwise agrees in writing during the Transition Services
       Period, Distributor shall have no obligation to provide: (i) any
       additional services or activities that were not contemplated by the
       Parties in preparing the 2004 Plan; or (ii) any services or activities
       that are of a nature or timing or at a volume, level or quality of
       services or activities that exceed those contemplated by the Parties in
       preparing the 2004 Plan.

       4.2    PRORATION. In the event of any partial payment of any invoice
       covering both Hospira Products and other products of Distributor, the
       amount collected by Distributor from the customer shall be allocated to
       Hospira in the same proportion that the amount of the invoice for the
       Products bears to the total amount of the invoice. Any interest

                                    7

<Page>

       recovered or out-of-pocket expenses incurred in connection with the
       collection of an invoice covering both Products and other products of
       Distributor shall be allocated to Hospira in the same proportion that the
       amount of the invoice for the Products bears to the total invoice.

       4.3    DISCLAIMER. (a) EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT,
       EACH PARTY ACKNOWLEDGES AND AGREES THAT ALL SERVICES AND PRODUCTS ARE
       PROVIDED ON AN "AS-IS" BASIS AND DISTRIBUTOR MAKES NO WARRANTIES, EXPRESS
       OR IMPLIED, AND HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY OF
       MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, NON-INFRINGEMENT OR
       ANY OTHER WARRANTY WHATSOEVER; and (b) notwithstanding anything to the
       contrary herein: (i) Distributor shall not be required to perform or
       cause to be performed any Distributor Activities or any other service or
       activity for the benefit of any Party other than Hospira and any Hospira
       Subsidiary; and (ii) Distributor shall have no obligation to Hospira for
       any Liabilities relating to, arising out of, or resulting from the
       Distributor Activities except to the extent that such Liabilities relate
       to, arise out of or result from (A) Distributor's gross negligence or
       willful misconduct or (B) Distributor's payment obligations pursuant to
       this Agreement.

       4.4    ADHERENCE TO GUIDELINES. Each of Hospira and Distributor hereby
       agrees and covenants that during the Term it shall adhere to the
       guidelines for Distributor Activities set forth in SCHEDULE 5 of this
       Agreement (the "GUIDELINES").

5.     INDEMNIFICATION

       5.1    INDEMNIFICATION BY HOSPIRA. Hospira shall, to the fullest extent
       permitted by law, indemnify, defend and hold Distributor harmless against
       and in respect of any Liabilities relating to, arising out of, or
       resulting from: (i) Distributor's performance of this Agreement; and (ii)
       the Delayed Ex-U.S. Commercial Assets and Delayed Ex-U.S. Commercial
       Liabilities held by Distributor; PROVIDED, HOWEVER, that Hospira shall
       not be required to indemnify Distributor to the extent any such
       Liabilities relate to, arise out of, or result from the gross negligence
       or willful misconduct of Distributor in performing this Agreement.

       5.2    INDEMNIFICATION BY DISTRIBUTOR. Distributor shall, to the fullest
       extent permitted by law, indemnify, defend and hold harmless Hospira
       against and in respect of any

                                    8

<Page>

       Liabilities relating to, arising out of, or resulting from the gross
       negligence or willful misconduct of Distributor in performing this
       Agreement.

6.     EFFECTIVE TIME AND TERM

       6.1    TERM. This Agreement shall become effective at the Effective Time
       and shall remain in effect for a term expiring on the second anniversary
       of the Distribution Date unless: (i) terminated by Hospira on an earlier
       date by initiating the Local Closing in accordance with the provisions of
       SECTION 6.2; or (ii) extended due to an event of force majeure in
       accordance with SECTION 8.1 (the "TERM").

       6.2    LOCAL CLOSING. Hospira shall be entitled to initiate a Local
       Closing at any time during the Term by giving Distributor at least ninety
       (90) days' prior written notice of such Local Closing (the "NOTICE OF
       LOCAL CLOSING"). In the Notice of Local Closing Hospira shall identify
       the name and address of the Purchaser.

       6.3    SURVIVAL. The provisions of SECTION 4.3, ARTICLE 5, SECTION 8.3,
       SECTION 8.4, SECTION 8.6, SECTION 8.8, SECTION 8.9, SECTION 8.10, SECTION
       8.11 and SECTION 8.12 of this Agreement, any outstanding payment
       obligations under ARTICLE 3 and any outstanding payment, invoicing and
       wind down obligations under ARTICLE 7 shall survive the termination of
       this Agreement and shall remain in full force and effect thereafter.

7.     PURCHASE OF ASSETS AND ASSUMPTION OF LIABILITIES

       7.1    LOCAL CLOSING. Except as otherwise provided in SECTION 7.5 below,
       at the expiration or termination of the Term pursuant to ARTICLE 6, there
       will be a local closing (the "LOCAL CLOSING") to evidence and effectuate:
       (i) transfer of all legal title to and physical possession of all the
       Delayed Ex-U.S. Commercial Assets owned by Distributor (other than the
       Factored Assets) as of date of the Local Closing (the "CLOSING DATE") to
       Purchaser; and (ii) the assumption by Purchaser of all Delayed Ex-U.S.
       Commercial Liabilities of Distributor (other than Factored Liabilities
       and intercompany trade payables related to the Products) outstanding as
       of the Closing Date. Any Delayed Ex-U.S. Commercial Liabilities that are
       included in the calculation of the Fixed Fee Retainer shall not be
       considered Delayed Ex-U.S. Commercial Liabilities as of the Closing Date
       and shall be paid in accordance with the provisions of SECTION 7.6 of
       this Agreement. The Closing Date must occur on the last business day of a
       month and must occur on or before the last day of the Term.

                                    9

<Page>

       7.2    FACTORED ASSETS AND FACTORED LIABILITIES. Any Delayed Ex-U.S.
       Commercial Assets or Delayed Ex-U.S. Commercial Liabilities (such as
       trade receivables and certain Third Party Liabilities) that cannot be
       legally or practically transferred to or assumed by Purchaser at the
       Local Closing (respectively, the "FACTORED ASSETS" and "FACTORED
       LIABILITIES") and intercompany trade payables related to the Products:
       (i) shall not be included as part of the Delayed Ex-U.S. Commercial
       Assets and the Delayed Ex-U.S. Commercial Liabilities to be transferred
       to Purchaser; (ii) shall not be considered as Hospira Assets or Hospira
       Liabilities after the Local Closing; and (iii) shall be retained by
       Distributor. In order to reflect the time value of money, the Parties
       shall calculate the Factoring Adjustment.

       7.3    ASSET PURCHASE AND LIABILITY ASSUMPTION. On the Closing Date,
       Distributor shall sell, transfer, convey and deliver to Purchaser, and
       Purchaser shall purchase and accept delivery of, all Delayed Ex-U.S.
       Commercial Assets owned by Distributor (other than Factored Assets) as of
       the Closing Date and Purchaser shall accept, assume and agree faithfully
       to perform, discharge and fulfill the Delayed Ex-U.S. Commercial
       Liabilities of Distributor (other than Factored Liabilities and
       intercompany trade payables related to the Products) outstanding as of
       the Closing Date in exchange for a purchase price equal to: (i) the Net
       Asset Value of the Delayed Ex-U.S. Commercial Assets and Delayed Ex-U.S.
       Commercial Liabilities transferred as of the Closing Date; plus (ii) the
       Factoring Adjustment (the "PURCHASE PRICE"). The Purchase Price shall be
       paid in accordance with the provisions of SECTION 7.4 below.

       7.4    INVOICE AND PAYMENT. Within twenty (20) days following the Closing
       Date, Distributor shall (a) prepare and deliver to each of Hospira and
       Purchaser a report (the "CLOSING REPORT") setting forth: (i) a list
       identifying all of the Delayed Ex-U.S. Commercial Assets and Delayed
       Ex-U.S. Commercial Liabilities transferred to or assumed by Purchaser at
       the Local Closing which shall contain the information regarding such
       Delayed Ex-U.S. Commercial Assets and Delayed Ex-U.S. Commercial
       Liabilities, and be in such format or formats, as is available from the
       books and records of Distributor; (ii) the Net Book Value of all Delayed
       Ex-U.S. Commercial Assets transferred by Distributor to Purchaser at the
       Local Closing and the Book Value of all Delayed Ex-U.S. Commercial
       Liabilities assumed by Purchaser at the Local Closing; (iii) the Net Book
       Value of the Factored Assets and the Book Value of the Factored
       Liabilities; (iv) the Book Value of the intercompany trade payables
       related to the Products; (v) the amount of the Factoring Adjustment; and
       (vi) the Purchase Price; and (b) provide an invoice to Purchaser stating
       the Purchase Price plus any applicable value

                                    10

<Page>

       added Taxes, sales Taxes or transfer Taxes or any similar Taxes payable
       by Purchaser in accordance with the provisions of applicable law.
       Purchaser shall pay the amount so invoiced within thirty (30) days from
       the date of Distributor's invoice. The Purchase Price plus any applicable
       Taxes shall be paid in the local currency of Distributor in accordance
       with payment instructions to be provided by Distributor.

       7.5    FAILURE TO CLOSE. Subject to the provisions of SECTION 8.1, if
       Hospira does not provide Notice of Local Closing at least ninety (90)
       days prior to the end of the Term, the following shall be applicable as
       of the end of the Term:

              (a)    Except as otherwise provided in SECTION 7.5(d) below,
                     Distributor shall not have any responsibility, liability or
                     obligation to Hospira with respect to the Delayed Ex-U.S.
                     Commercial Assets and Delayed Ex-U.S. Commercial
                     Liabilities in the Territory;

              (b)    Within twenty (20) days following the end of the Term,
                     Distributor shall provide an invoice to Hospira indicating
                     the Purchase Price calculated as if the Local Closing had
                     taken place as of the end of the Term and Hospira shall pay
                     the invoice within thirty (30) days from the date of such
                     invoice;

              (c)    As of the end of the Term, Distributor shall immediately
                     cease all Distributor Activities related to the Products,
                     except to the extent necessary for Distributor to satisfy
                     its remaining contracts, commitments or other legal
                     obligations in the Territory related to the Products; and

              (d)    Subject to the provisions of SECTION 7.5(c), Distributor
                     shall proceed to liquidate all the Delayed Ex-U.S.
                     Commercial Assets existing as of the end of the Term and
                     pay all Delayed Ex-U.S. Commercial Liabilities outstanding
                     as of the end of the Term and, following the completion of
                     the wind down activities, to remit the proceeds from such
                     wind down to Hospira, net of Delayed Ex-U.S. Commercial
                     Liabilities and the costs incurred by Distributor in
                     connection with such wind down activities.

       7.6    PAYMENT OF THE FINAL FIXED FEE RETAINER AND INTEREST PAYMENT.
       Within twenty (20) days following the Closing Date or the end of the
       Term, Distributor shall provide to Hospira an invoice indicating the
       Fixed Fee Retainer and any other amounts due under the provisions of
       SECTION 3.2, in each case for the last month of the Term. Hospira shall
       pay the amount so invoiced within thirty (30) days of the date of the
       invoice.

                                    11

<Page>

8.     MISCELLANEOUS.

       8.1    FORCE MAJEURE.  Neither Party shall be deemed in default of this
       Agreement to the extent that any delay or failure in the performance of
       its obligations under this Agreement results from any cause beyond its
       reasonable control and without its fault or negligence, such as acts of
       God, acts of a Governmental Authority, embargoes, epidemics, war, riots,
       insurrections, acts of terrorism, fires, explosions, earthquakes, floods,
       unusually severe weather conditions, labor problems or unavailability of
       parts, or, in the case of computer systems, any failure in electrical or
       air conditioning equipment. In the event of any such excused delay, the
       time for performance shall be extended for a period equal to the time
       lost by reason of the delay. Notwithstanding the foregoing, the Local
       Closing shall not be delayed pursuant to this Section beyond the date
       that is thirty (30) months after the Effective Time.

       8.2    COUNTERPARTS.  This Agreement may be executed in one or more
       counterparts, all of which shall be considered one and the same
       agreement.

       8.3    GOVERNING LAW.  This Agreement shall be governed by and construed
       and interpreted in accordance with the laws of the State of Illinois
       irrespective of the choice of laws principles of the State of Illinois,
       as to all matters, including matters of validity, construction, effect,
       enforceability, performance and remedies.

       8.4    DISPUTE RESOLUTION.  Any controversy, dispute or claim (whether
       arising in contract, tort or otherwise) arising out of or relating in any
       way to this Agreement shall be resolved pursuant to the procedures set
       forth in SCHEDULE 6 of this Agreement. Unless otherwise agreed in
       writing, the Distributor shall continue to perform Distributor Activities
       in accordance with the provisions of this Agreement during the course of
       any dispute, but in no event shall such Distributor Activities extend
       beyond the second anniversary of the Distribution Date, unless the Local
       Closing is delayed under SECTION 8.1.

       8.5    ASSIGNABILITY.  This Agreement shall be binding upon and inure to
       the benefit of the Parties hereto and their respective successors and
       permitted assigns; PROVIDED, HOWEVER, that neither Party may assign its
       rights or delegate its obligations under this Agreement without the
       express prior written consent of the other Party hereto. Notwithstanding
       the foregoing, this Agreement shall be assignable by either Party in
       whole with the prior written consent of the other Party (which consent
       shall not be unreasonably withheld, delayed or conditioned) in connection
       with: (i) a merger or

                                    12

<Page>

       consolidation of such Party; (ii) the sale of all or substantially all of
       the assets of such Party; or (iii) the acquisition by a Third Party of at
       least 30% of the combined voting power of the then-outstanding securities
       of such Party entitled to vote generally in the election of directors, in
       each case so long as the resulting, surviving or transferee Person
       assumes all the obligations of the assignor hereunder by operation of law
       or pursuant to an agreement in form and substance reasonably satisfactory
       to the other Party. It shall not be deemed to be unreasonable for a Party
       to withhold consent to such an assignment on the basis that the proposed
       assignee is a competitor of such Party.

       8.6    NOTICES. All notices or other communications under this Agreement
       must be in writing and shall be deemed to be duly given: (i) when
       delivered in person; (ii) upon transmission via confirmed facsimile
       transmission, provided that such transmission is followed by delivery of
       a physical copy thereof in person, via U.S. first class mail, or via a
       private express mail courier; or (iii) two (2) days after deposit with a
       private express mail courier, in any such case addressed as set forth on
       SCHEDULE 7 of this Agreement. Any Party may, by notice to the other
       Party, change the address to which such notices are to be given.

       8.7    SEVERABILITY. If any provision of this Agreement or the
       application thereof to any entity or person or circumstance is determined
       by a court of competent jurisdiction to be invalid, void or
       unenforceable, the remaining provisions hereof, or the application of
       such provision to any entity or person or circumstances or in
       jurisdictions other than those as to which it has been held invalid or
       unenforceable, shall remain in full force and effect and shall in no way
       be affected, impaired or invalidated thereby, so long as the economic or
       legal substance of the transactions contemplated hereby is not affected
       in any manner adverse to any Party. Upon such determination, the Parties
       shall negotiate in good faith in an effort to agree upon such a suitable
       and equitable provision to effect the original intent of the Parties.

       8.8    WAIVERS OF DEFAULT. Waiver by either Party of any default by the
       other Party of any provision of this Agreement shall not be deemed a
       waiver by the waiving Party of any subsequent or other default, nor shall
       it prejudice the rights of the other Party.

       8.9    HEADINGS.  The article, section and paragraph headings contained
       in this Agreement are for reference purposes only and shall not affect in
       any way the meaning or interpretation of this Agreement.

                                    13

<Page>

       8.10   AMENDMENTS.  No provisions of this Agreement shall be deemed
       amended, supplemented or modified unless such amendment, supplement or
       modification is in writing and signed by the authorized representative of
       both Parties. No provisions of this Agreement shall be deemed waived
       unless such waiver is in writing and signed by the authorized
       representative of the Party against whom it is sought to be enforced.

       8.11   INTERPRETATION.  Words in the singular shall be deemed to include
       the plural and vice versa and words of one gender shall be deemed to
       include the other genders as the context requires. The terms "hereof,"
       "herein," and "herewith" and words of similar import shall, unless
       otherwise stated, be construed to refer to this Agreement as a whole
       (including all of the Schedules hereto) and not to any particular
       provision of this Agreement. Article, section, and schedule references
       are to the articles, sections, and schedules to this Agreement unless
       otherwise specified. Unless otherwise stated, all references to any
       agreement shall be deemed to include the exhibits, schedules and annexes
       to such agreement. The word "including" and words of similar import when
       used in this Agreement shall mean "including, without limitation," unless
       the context otherwise requires or unless otherwise specified. The word
       "or" shall not be exclusive. Unless otherwise specified in a particular
       case, the word "days" refers to calendar days. References herein to this
       Agreement shall be deemed to refer to this Agreement as of the Effective
       Time and as it may be amended thereafter, unless otherwise specified.

       8.12   MUTUAL DRAFTING.  This Agreement shall be deemed to be the joint
       work product of the Parties and any rule of construction that a document
       shall be interpreted or construed against a drafter of such document
       shall not be applicable.

                                     * * * *

       IN WITNESS WHEREOF, the Parties have caused this Transition Marketing and
Distribution Services Agreement to be executed as of the date first written
above.

[DISTRIBUTOR]                           HOSPIRA, INC.

--------------------------------------  ----------------------------------------
By:                                     By:
Title:                                  Title:

                                    14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]